AGXT and neoplasm: Our validation of the SPT-R signature in an extended PDX cohort correctly identified 4 additional NR tumors, and all NEPCs and double-negative PC PDX models that do not express AR had low SPT-R signature scores, indicating an SPT NR tumor.